500 related articles for article (PubMed ID: 28988289)
21. Germline TP53 Mutations in Patients With Early-Onset Colorectal Cancer in the Colon Cancer Family Registry.
Yurgelun MB; Masciari S; Joshi VA; Mercado RC; Lindor NM; Gallinger S; Hopper JL; Jenkins MA; Buchanan DD; Newcomb PA; Potter JD; Haile RW; Kucherlapati R; Syngal S;
JAMA Oncol; 2015 May; 1(2):214-21. PubMed ID: 26086041
[TBL] [Abstract][Full Text] [Related]
22. Penetrance Estimates Over Time to First and Second Primary Cancer Diagnosis in Families with Li-Fraumeni Syndrome: A Single Institution Perspective.
Shin SJ; Dodd-Eaton EB; Gao F; Bojadzieva J; Chen J; Kong X; Amos CI; Ning J; Strong LC; Wang W
Cancer Res; 2020 Jan; 80(2):347-353. PubMed ID: 31719099
[TBL] [Abstract][Full Text] [Related]
23. TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes.
Ruijs MW; Verhoef S; Rookus MA; Pruntel R; van der Hout AH; Hogervorst FB; Kluijt I; Sijmons RH; Aalfs CM; Wagner A; Ausems MG; Hoogerbrugge N; van Asperen CJ; Gomez Garcia EB; Meijers-Heijboer H; Ten Kate LP; Menko FH; van 't Veer LJ
J Med Genet; 2010 Jun; 47(6):421-8. PubMed ID: 20522432
[TBL] [Abstract][Full Text] [Related]
24. Transmission of a
Cotter JA; Szymanski L; Karimov C; Boghossian L; Margol A; Dhall G; Tamrazi B; Varaprasathan GI; Parham DM; Judkins AR; Biegel JA
Cold Spring Harb Mol Case Stud; 2018 Apr; 4(2):. PubMed ID: 29581140
[TBL] [Abstract][Full Text] [Related]
25. Li-Fraumeni Syndrome and Whole-Body MRI Screening: Screening Guidelines, Imaging Features, and Impact on Patient Management.
Consul N; Amini B; Ibarra-Rovira JJ; Blair KJ; Moseley TW; Taher A; Shah KB; Elsayes KM
AJR Am J Roentgenol; 2021 Jan; 216(1):252-263. PubMed ID: 33151095
[TBL] [Abstract][Full Text] [Related]
26. Joint effects of germ-line TP53 mutation, MDM2 SNP309, and gender on cancer risk in family studies of Li-Fraumeni syndrome.
Wu CC; Krahe R; Lozano G; Zhang B; Wilson CD; Jo EJ; Amos CI; Shete S; Strong LC
Hum Genet; 2011 Jun; 129(6):663-73. PubMed ID: 21305319
[TBL] [Abstract][Full Text] [Related]
27. Identification and Management of
Pal T; Brzosowicz J; Valladares A; Wiesner GL; Laronga C
South Med J; 2017 Oct; 110(10):643-648. PubMed ID: 28973705
[TBL] [Abstract][Full Text] [Related]
28. Cancer Screening Recommendations for Individuals with Li-Fraumeni Syndrome.
Kratz CP; Achatz MI; Brugières L; Frebourg T; Garber JE; Greer MC; Hansford JR; Janeway KA; Kohlmann WK; McGee R; Mullighan CG; Onel K; Pajtler KW; Pfister SM; Savage SA; Schiffman JD; Schneider KA; Strong LC; Evans DGR; Wasserman JD; Villani A; Malkin D
Clin Cancer Res; 2017 Jun; 23(11):e38-e45. PubMed ID: 28572266
[TBL] [Abstract][Full Text] [Related]
29. TP53 germline mutation may affect response to anticancer treatments: analysis of an intensively treated Li-Fraumeni family.
Kappel S; Janschek E; Wolf B; Rudas M; Teleky B; Jakesz R; Kandioler D
Breast Cancer Res Treat; 2015 Jun; 151(3):671-8. PubMed ID: 25981898
[TBL] [Abstract][Full Text] [Related]
30. [Li-Fraumeni syndrome - a proposal of complex prevention care for carriers of TP53 mutation with total-body MRI].
Foretová L; Stěrba J; Opletal P; Mach V; Lisý J; Petráková K; Palácová M; Navrátilová M; Gaillyová R; Puchmajerová A; Křepelová A; Macháčková E
Klin Onkol; 2012; 25 Suppl():S49-54. PubMed ID: 22920207
[TBL] [Abstract][Full Text] [Related]
31. TP53 and CDKN1A mutation analysis in families with Li-Fraumeni and Li-Fraumeni like syndromes.
Andrade RC; Dos Santos AC; de Aguirre Neto JC; Nevado J; Lapunzina P; Vargas FR
Fam Cancer; 2017 Apr; 16(2):243-248. PubMed ID: 27714481
[TBL] [Abstract][Full Text] [Related]
32. Germline TP53 mutations and the changing landscape of Li-Fraumeni syndrome.
Kamihara J; Rana HQ; Garber JE
Hum Mutat; 2014 Jun; 35(6):654-62. PubMed ID: 24706533
[TBL] [Abstract][Full Text] [Related]
33. Case Report : Li-Fraumeni Syndrome with Central Nervous System Tumors in Two Siblings.
Fang Z; Su Y; Sun H; Ge M; Qi Z; Hao C; Qian S; Ma X
BMC Pediatr; 2021 Dec; 21(1):588. PubMed ID: 34961499
[TBL] [Abstract][Full Text] [Related]
34. Choroid plexus tumors; management, outcome, and association with the Li-Fraumeni syndrome: the Children's Hospital Los Angeles (CHLA) experience, 1991-2010.
Gozali AE; Britt B; Shane L; Gonzalez I; Gilles F; McComb JG; Krieger MD; Lavey RS; Shlien A; Villablanca JG; Erdreich-Epstein A; Dhall G; Jubran R; Tabori U; Malkin D; Finlay JL
Pediatr Blood Cancer; 2012 Jun; 58(6):905-9. PubMed ID: 21990040
[TBL] [Abstract][Full Text] [Related]
35. A novel TP53 germline inframe deletion identified in a Spanish series of Li-fraumeni syndrome suspected families.
Llovet P; Illana FJ; Martín-Morales L; de la Hoya M; Garre P; Ibañez-Royo MD; Pérez-Segura P; Caldés T; García-Barberán V
Fam Cancer; 2017 Oct; 16(4):567-575. PubMed ID: 28573494
[TBL] [Abstract][Full Text] [Related]
36. Early detection of adrenocortical carcinoma in a child with Li-Fraumeni syndrome.
Lin MT; Shieh JJ; Chang JH; Chang SW; Chen TC; Hsu WH
Pediatr Blood Cancer; 2009 Apr; 52(4):541-4. PubMed ID: 19101993
[TBL] [Abstract][Full Text] [Related]
37. F18-fluorodeoxyglucose-positron emission tomography/computed tomography screening in Li-Fraumeni syndrome.
Masciari S; Van den Abbeele AD; Diller LR; Rastarhuyeva I; Yap J; Schneider K; Digianni L; Li FP; Fraumeni JF; Syngal S; Garber JE
JAMA; 2008 Mar; 299(11):1315-9. PubMed ID: 18349092
[TBL] [Abstract][Full Text] [Related]
38. Radiation therapy and secondary malignancy in Li-Fraumeni syndrome: A hereditary cancer registry study.
Hendrickson PG; Luo Y; Kohlmann W; Schiffman J; Maese L; Bishop AJ; Lloyd S; Kokeny KE; Hitchcock YJ; Poppe MM; Gaffney DK; Tao R
Cancer Med; 2020 Nov; 9(21):7954-7963. PubMed ID: 32931654
[TBL] [Abstract][Full Text] [Related]
39. Cancer surveillance and distress among adult pathogenic TP53 germline variant carriers in Germany: A multicenter feasibility and acceptance survey.
Rippinger N; Fischer C; Haun MW; Rhiem K; Grill S; Kiechle M; Cremer FW; Kast K; Nguyen HP; Ditsch N; Kratz CP; Vogel J; Speiser D; Hettmer S; Glimm H; Fröhling S; Jäger D; Seitz S; Hahne A; Maatouk I; Sutter C; Schmutzler RK; Dikow N; Schott S
Cancer; 2020 Sep; 126(17):4032-4041. PubMed ID: 32557628
[TBL] [Abstract][Full Text] [Related]
40. TP53 p.R337H is a conditional cancer-predisposing mutation: further evidence from a homozygous patient.
Giacomazzi J; Selistre S; Duarte J; Ribeiro JP; Vieira PJ; de Souza Macedo G; Rossi C; Czepielewski M; Netto CB; Hainaut P; Ashton-Prolla P
BMC Cancer; 2013 Apr; 13():187. PubMed ID: 23570263
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
